



FOR IMMEDIATE RELEASE

## **Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month**

*Two poster presentations will present new COM701 and COM902 data*

HOLON, ISRAEL – October 26, 2017 – [Compugen Ltd.](#) (NASDAQ: [CGEN](#)), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced it will present two posters with new data on COM701, the Company's first-in-class immuno-oncology therapeutic antibody candidate targeting PVRIG, and COM902, the Company's immuno-oncology therapeutic antibody targeting TIGIT, at the [32<sup>nd</sup> Annual Meeting of the Society for Immunotherapy of Cancer](#) to be held November 8-12 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.

The poster titled "Analysis of the TIGIT/PVRIG axis in human cancers to support indication selection and biomarkers for COM701 and COM902" (Poster no. P369) will be presented on Friday, November 10, 2017 at 12:30-2 pm and 6:30-8 pm ET.

The poster titled "Development and functional characterization of COM902, a novel therapeutic antibody targeting the immune checkpoint TIGIT" (Poster no. P344) will be presented on Saturday, November 11, 2017 at 12:30-2 pm and 6:30-8 pm ET.

Anat Cohen-Dayag, PhD, President and CEO of Compugen, stated, "We are excited to be presenting new data at the SITC meeting on COM701 and COM902, our two lead programs in our internal immuno-oncology pipeline. Our development strategy for these two programs, based on the biology of the PVRIG-TIGIT axis, includes opportunities for both monotherapy as well as dual- and triple-combination treatment options with PD-1 blockers. We see an opportunity to potentially generate significant therapeutic value for patients using our approach for drug combination."

Following the presentations, the posters will be available on Compugen's website at [www.cgen.com](http://www.cgen.com).

### **About COM701 and COM902**

COM701 is a humanized hybridoma antibody that binds with high affinity to PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen, blocking its

interaction with PVRL2. Blockade of PVRIG by COM701 has demonstrated potent, reproducible enhancement of T cell activation, consistent with the desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses. COM902, Compugen's therapeutic antibody targeting TIGIT, was developed for combination use with COM701. Preclinical data strongly support combining COM701 with TIGIT antagonist antibodies. Dual blockade of the two negative costimulatory arms of the axis – TIGIT and PVRIG – results in a more robust T cell response to antigen stimulation, and therefore may possibly result in better anti-tumor immune response. In addition, COM701 combined with antagonist anti-PD1 antibodies has demonstrated synergistic effect on human T cell stimulation, indicating the potential of these combinations to further enhance immune response against tumors.

### **About Compugen**

Compugen is a therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with R&D facilities in both Israel and South San Francisco, CA. Compugen's shares are listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at <http://www.cgen.com>.

### **Forward-Looking Statement**

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," and "intends," and describe opinions about possible future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model. Moreover, the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to clinical trials or, if they progress to or enter clinical trials, failure to receive regulatory approval. These and other factors are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

**Company contact:**

Elana Holzman

Director, Investor Relations and Corporate Communications

Compugen Ltd.

Email: [elanah@cgen.com](mailto:elanah@cgen.com)

Tel: +972 (3) 765-8124